MX2020002802A - Anticuerpos de cadena pesada que se unen a ectoenzimas. - Google Patents

Anticuerpos de cadena pesada que se unen a ectoenzimas.

Info

Publication number
MX2020002802A
MX2020002802A MX2020002802A MX2020002802A MX2020002802A MX 2020002802 A MX2020002802 A MX 2020002802A MX 2020002802 A MX2020002802 A MX 2020002802A MX 2020002802 A MX2020002802 A MX 2020002802A MX 2020002802 A MX2020002802 A MX 2020002802A
Authority
MX
Mexico
Prior art keywords
ectoenzymes
heavy chain
chain antibodies
antibodies
antibodies binding
Prior art date
Application number
MX2020002802A
Other languages
English (en)
Inventor
Nathan Trinklein
Schooten Wim Van
Shelley Force Aldred
Kevin Dang
Starlynn Clarke
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of MX2020002802A publication Critical patent/MX2020002802A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Los anticuerpos humanos de cadena pesada tales como los UniAbsTM que se unen a ectoenzimas se proporcionan junto con combinaciones de dichos anticuerpos de cadena pesada y anticuerpos de cadena pesada multiespecíficos que se dirigen a epítopos que no se superponen en ectoenzimas, lo que incluye combinaciones sinérgicas. Se incluyen también métodos para elaborar dichos anticuerpos, composiciones que incluyen composiciones farmacéuticas que comprenden dichos anticuerpos y métodos dirigidos al tratamiento de enfermedades o afecciones que se asocian con la expresión de ectoenzimas.
MX2020002802A 2017-09-13 2018-09-13 Anticuerpos de cadena pesada que se unen a ectoenzimas. MX2020002802A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558147P 2017-09-13 2017-09-13
PCT/US2018/050931 WO2019055689A1 (en) 2017-09-13 2018-09-13 HEAVY CHAIN ANTIBODIES BINDING TO EXOENZYMES

Publications (1)

Publication Number Publication Date
MX2020002802A true MX2020002802A (es) 2020-10-12

Family

ID=63714117

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002802A MX2020002802A (es) 2017-09-13 2018-09-13 Anticuerpos de cadena pesada que se unen a ectoenzimas.

Country Status (13)

Country Link
US (1) US20200207867A1 (es)
EP (1) EP3681908A1 (es)
JP (1) JP2020533362A (es)
KR (1) KR20200044094A (es)
CN (1) CN111133007A (es)
AU (1) AU2018331421A1 (es)
BR (1) BR112020004846A2 (es)
CA (1) CA3075399A1 (es)
IL (1) IL273235A (es)
MX (1) MX2020002802A (es)
RU (1) RU2020112490A (es)
SG (1) SG11202002093TA (es)
WO (1) WO2019055689A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017316604C1 (en) 2016-08-24 2025-01-30 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio, Inc. anticorpos apenas de cadeia pesada anti-bcma
CA3086665A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
AU2020252556B2 (en) 2019-04-05 2026-02-05 Teneobio, Inc. Heavy chain antibodies binding to PSMA
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
WO2021127489A1 (en) * 2019-12-18 2021-06-24 Teneobio, Inc. Heavy chain antibodies binding to cd38
KR20220169488A (ko) 2020-03-16 2022-12-27 유니버시티 오브 써던 캘리포니아 신규한 항원 결합 도메인 및 이를 포함하는 합성 항원 수용체
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP4353819A3 (en) 2004-07-22 2024-07-17 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
KR20150139636A (ko) 2005-10-12 2015-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
WO2007055916A2 (en) 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
CN101426815A (zh) * 2005-12-06 2009-05-06 杜门蒂斯有限公司 具有表皮生长因子受体和/或血管内皮生长因子结合特异性的配体及其使用方法
NZ572379A (en) 2006-04-05 2012-06-29 Univ Rockefeller Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR102096731B1 (ko) 2007-06-01 2020-04-02 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
AU2010224160A1 (en) 2009-03-10 2011-09-22 Biogen Idec Ma Inc. Anti-BCMA antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011100403A1 (en) * 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
EP3613774A1 (en) 2010-06-09 2020-02-26 Genmab A/S Antibodies against human cd38
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US20150118251A1 (en) * 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
EP3066133A1 (en) * 2013-11-04 2016-09-14 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
KR102497443B1 (ko) * 2014-03-28 2023-02-08 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
BR112017024877A2 (pt) * 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017081211A2 (en) * 2015-11-10 2017-05-18 University Medical Center Hamburg - Eppendorf Antigen-binding polypeptides directed against cd38

Also Published As

Publication number Publication date
RU2020112490A (ru) 2021-10-13
EP3681908A1 (en) 2020-07-22
CN111133007A (zh) 2020-05-08
BR112020004846A2 (pt) 2020-09-15
IL273235A (en) 2020-04-30
SG11202002093TA (en) 2020-04-29
RU2020112490A3 (es) 2022-03-28
JP2020533362A (ja) 2020-11-19
AU2018331421A1 (en) 2020-04-30
AU2018331421A2 (en) 2020-05-28
KR20200044094A (ko) 2020-04-28
US20200207867A1 (en) 2020-07-02
CA3075399A1 (en) 2019-03-21
WO2019055689A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
ZA202201874B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
JOP20200157B1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
MY203971A (en) Anti-lag-3 antibodies and compositions
MX2022001105A (es) Anticuerpos anti tigit.
EA201992350A1 (ru) Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
PH12021553145A1 (en) Multispecific heavy chain antibodies binding to cd22 and cd3
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MY197866A (en) Anti-cd27 antibodies
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
NZ743049A (en) Anti-cd3-folate conjugates and their uses
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
TW202608484A (zh) 抗-SIRPα 抗體
HK1238261A1 (en) Novel anti-mfi2 antibodies and methods of use